This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trujillano-Martín, I.
Right arrow Articles by García-Rodríguez, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trujillano-Martín, I.
Right arrow Articles by García-Rodríguez, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 194-195, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activities of Six New Fluoroquinolones against Brucella melitensis

Ignacio Trujillano-Martín,1 Enrique García-Sánchez,1 Isaías Montes Martínez,2 María José Fresnadillo,1 José Elías García-Sánchez,1 and José Ángel García-Rodríguez1,*

Departamento de Microbiología y Parasitología, Hospital Universitario, Salamanca,1 and Unidad de Microbiología, Hospital Virgen del Puerto, Plasencia, Cáceres,2 Spain

Received 24 June 1998/Returned for modification 13 August 1998/Accepted 23 October 1998

We have tested the in vitro activities of eight fluoroquinolones against 160 Brucella melitensis strains. The most active was sitafloxacin (MIC at which 90% of the isolates are inhibited [MIC90], 0.12 µg/ml). In decreasing order, the activities (MIC90s) of the rest of the tested fluoroquinolones were as follows: levofloxacin, 0.5 µg/ml; ciprofloxacin, trovafloxacin, and moxifloxacin, 1 µg/ml; and ofloxacin, grepafloxacin, and gatifloxacin, 2 µg/ml.

* Corresponding author. Mailing address: Department of Microbiology, Hospital Universitario, Paseo de San Vicente 108, 37007 Salamanca, Spain. Phone: 34-23-264825. Fax: 34-23-262261. E-mail: jagarrod{at}gugu.usal.es.

Antimicrobial Agents and Chemotherapy, January 1999, p. 194-195, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Valdezate, S., Navarro, A., Medina-Pascual, M. J., Carrasco, G., Saez-Nieto, J. A. (2009). Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis. J Antimicrob Chemother 0: dkp389v1-dkp389 [Abstract] [Full Text]  
  • Falagas, M. E., Bliziotis, I. A. (2006). Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. Antimicrob. Agents Chemother. 50: 22-33 [Full Text]  
  • Brown, S. D., Traczewski, M. M., the Brucella QC Working Group, (2005). Broth Microdilution Susceptibility Testing of Brucella Species: Quality Control Limits for Ten Antimicrobial Agents against Three Standard Quality Control Strains. J. Clin. Microbiol. 43: 5804-5807 [Abstract] [Full Text]  
  • Maurin, M., Raoult, D. (2001). Use of Aminoglycosides in Treatment of Infections Due to Intracellular Bacteria. Antimicrob. Agents Chemother. 45: 2977-2986 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»